IMCC
IM Cannabis Corp.·Healthcare
0.27
5.000%(−0.01)
Close PriceLast Updated: — ET
52W L: $0.2252W H: $7.12
IMCC NEWS
prnewswire.com
May 13
IM Cannabis Corp. Announces First Quarter 2026 Financial Results
TORONTO and GLIL YAM, Israel, May 13, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated.
prnewswire.com
May 7
IM Cannabis Raised US$550,000 of Gross Proceeds in Convertible Note Financings
TORONTO and GLIL YAM, Israel, May 7, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$300,000 convertible note financing in a private placement with an institutional investor, bringing the total gross proceeds raised in recent similar financings to US$550,000. First Note Pursuant to a note purchase agreement between the Company and Lender dated April 6, 2026 (the "First Note Purchase Agreement"), the Company issued the Lender a note in the principal amount of US$250,000, with an original issuance discount of 10% (the "First Note").
prnewswire.com
Apr 10
IMC Announces Receipt of Nasdaq Minimum Bid Price Notification
TORONTO and GLIL YAM, Israel, April 10, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.
defenseworld.net
Apr 6
Stryker (NYSE:SYK) & IM Cannabis (NASDAQ:IMCC) Critical Analysis
IM Cannabis (NASDAQ: IMCC - Get Free Report) and Stryker (NYSE: SYK - Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability. Profitability This table compares IM Cannabis and Stryker's net
prnewswire.com
Mar 31
IM Cannabis Reports 2025 Results: Revenue of C$54.7 Million with Over 134% Growth in Germany and Positive Operating Cash Flow
TORONTO and GLIL YAM, Israel, March 31, 2026 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today reported its audited consolidated financial results as of and for the full year ended December 31, 2025. The Company achieved a major operational milestone by generating positive cash flow from operating activities of C$4.7 million for the year ended December 31, 2025, a significant turnaround from negative cash flow in 2024, while delivering high revenue growth in Germany, completing financing transactions, and strengthening its cash position.
defenseworld.net
Mar 19
Analyzing Quanterix (NASDAQ:QTRX) & IM Cannabis (NASDAQ:IMCC)
Quanterix (NASDAQ: QTRX - Get Free Report) and IM Cannabis (NASDAQ: IMCC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk. Institutional and Insider Ownership 86.5% of Quanterix shares
